VIR-7831 (sotrovimab) + Placebo

Phase 2/3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
60
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Aug 27, 2020 โ†’ Sep 2, 2021

About VIR-7831 (sotrovimab) + Placebo

VIR-7831 (sotrovimab) + Placebo is a phase 2/3 stage product being developed by Vir Biotechnology for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04545060. Target conditions include Covid19.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT04545060Phase 2/3Completed